Literature DB >> 11475535

Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications.

F V DeFeudis1, K Drieu.   

Abstract

The effects of EGb 761 on the CNS underlie one of its major therapeutic indications; i.e., individuals suffering from deteriorating cerebral mechanisms related to age-associated impairments of memory, attention and other cognitive functions. EGb 761 is currently used as symptomatic treatment for cerebral insufficiency that occurs during normal ageing or which may be due to degenerative dementia, vascular dementia or mixed forms of both, and for neurosensory disturbances. Depressive symptoms of patients with Alzheimer's disease (AD) and aged non-Alzheimer patients may also respond to treatment with EGb 761 since this extract has an "anti-stress" effect. Basic and clinical studies, conducted both in vitro and in vivo, support these beneficial neuroprotective effects of EGb 761. EGb 761 has several major actions; it enhances cognition, improves blood rheology and tissue metabolism, and opposes the detrimental effects of ischaemia. Several mechanisms of action are useful in explaining how EGb 761 benefits patients with AD and other age-related, neurodegenerative disorders. In animals, EGb 761 possesses antioxidant and free radical-scavenging activities, it reverses age-related losses in brain alpha 1-adrenergic, 5-HT1A and muscarinic receptors, protects against ischaemic neuronal death, preserves the function of the hippocampal mossy fiber system, increases hippocampal high-affinity choline uptake, inhibits the down-regulation of hippocampal glucocorticoid receptors, enhances neuronal plasticity, and counteracts the cognitive deficits that follow stress or traumatic brain injury. Identified chemical constituents of EGb 761 have been associated with certain actions. Both flavonoid and ginkgolide constituents are involved in the free radical-scavenging and antioxidant effects of EGb 761 which decrease tissue levels of reactive oxygen species (ROS) and inhibit membrane lipid peroxidation. Regarding EGb 761-induced regulation of cerebral glucose utilization, bilobalide increases the respiratory control ratio of mitochondria by protecting against uncoupling of oxidative phosphorylation, thereby increasing ATP levels, a result that is supported by the finding that bilobalide increases the expression of the mitochondrial DNA-encoded COX III subunit of cytochrome oxidase. With regard to its "anti-stress" effect, EGb 761 acts via its ginkgolide constituents to decrease the expression of the peripheral benzodiazepine receptor (PBR) of the adrenal cortex.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11475535     DOI: 10.2174/1389450003349380

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  76 in total

Review 1.  Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment.

Authors:  Vladimir Lerner; Chanoch Miodownik
Journal:  Curr Psychiatry Rep       Date:  2011-08       Impact factor: 5.285

2.  Effects of Ginkgo biloba extract on heart and liver mitochondrial functions: mechanism(s) of action.

Authors:  Giedre Baliutyte; Rasa Baniene; Sonata Trumbeckaite; Vilmante Borutaite; Adolfas Toleikis
Journal:  J Bioenerg Biomembr       Date:  2010-03-19       Impact factor: 2.945

3.  Study on Mechanism of Ginkgo biloba L. Leaves for the Treatment of Neurodegenerative Diseases Based on Network Pharmacology.

Authors:  Jing Wang; Xialin Chen; Weirong Bai; Zhenzhong Wang; Wei Xiao; Jingbo Zhu
Journal:  Neurochem Res       Date:  2021-05-14       Impact factor: 3.996

4.  Intra-amygdaloid infusion of Ginkgo biloba leaf extract (EGb761) facilitates fear-potentiated startle in rats.

Authors:  Yi-Ling Yang; Chia-Wen Hsieh; Yu-Yuan P Wo; Yi-Chung Yang; Kwok-Tung Lu
Journal:  Psychopharmacology (Berl)       Date:  2008-06-20       Impact factor: 4.530

5.  The role of the dorsal hippocampus on the Ginkgo biloba facilitation effect of fear extinction as assessed with fear-potentiated startle.

Authors:  Yu-Fang Shen; Yu-Hsuan Chou; Yi-Ling Yang; Kwok-Tung Lu
Journal:  Psychopharmacology (Berl)       Date:  2011-03-15       Impact factor: 4.530

Review 6.  Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease.

Authors:  Ghiam Yamin; Kenjiro Ono; Mohammed Inayathullah; David B Teplow
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 7.  Neuroprotective and Antioxidant Effect of Ginkgo biloba Extract Against AD and Other Neurological Disorders.

Authors:  Sandeep Kumar Singh; Saurabh Srivastav; Rudolph J Castellani; Germán Plascencia-Villa; George Perry
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

8.  Ginkgo biloba extract EGb 761 has anti-inflammatory properties and ameliorates colitis in mice by driving effector T cell apoptosis.

Authors:  Venkata S Kotakadi; Yu Jin; Anne B Hofseth; Lei Ying; Xiangli Cui; Suresh Volate; Alexander Chumanevich; Patricia A Wood; Robert L Price; Anna McNeal; Udai P Singh; Narendra P Singh; Mitzi Nagarkatti; Prakash S Nagarkatti; Lydia E Matesic; Karine Auclair; Michael J Wargovich; Lorne J Hofseth
Journal:  Carcinogenesis       Date:  2008-06-20       Impact factor: 4.944

9.  Application of GC/MS-based metabonomic profiling in studying the lipid-regulating effects of Ginkgo biloba extract on diet-induced hyperlipidemia in rats.

Authors:  Qi Zhang; Guang-ji Wang; Ji-ye A; Di Wu; Ling-ling Zhu; Bo Ma; Yu Du
Journal:  Acta Pharmacol Sin       Date:  2009-12       Impact factor: 6.150

10.  Gene Regulatory Effects of Ginkgo biloba Extract and Its Flavonol and Terpenelactone Fractions in Mouse Brain.

Authors:  Sabine Augustin; Gerald Rimbach; Kay Augustin; Rainer Cermak; Siegfried Wolffram
Journal:  J Clin Biochem Nutr       Date:  2009-10-28       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.